Results 1 to 10 of about 48,339 (161)

Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin [PDF]

Microbial Cell, 2014
The human pathology Wilson disease (WD) is characterized by toxic copper (Cu) accumulation in brain and liver, resulting in, among other indications, mitochondrial dysfunction and apoptosis of hepatocytes.
Pieter Spincemaille, Gursimran Chandhok, Andree Zibert, Hartmut Schmidt, Jef Verbeek, Patrick Chaltin, Bruno P.A. Cammue, David Cassiman, Karin Thevissen   +8 more
doaj   +6 more sources

Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator‐Induced Diaphragm Dysfunction in Rats [PDF]

Clinical and Translational Science, 2021
Mechanical ventilation (MV) is a life‐saving intervention for many critically ill patients. Unfortunately, prolonged MV results in the rapid development of inspiratory muscle weakness due to diaphragmatic atrophy and contractile dysfunction (termed ...
Stephanie E. Hall, Bumsoo Ahn, Ashley J. Smuder, Aaron B. Morton, J. Matthew Hinkley, Michael P. Wiggs, Kurt J. Sollanek, Hayden Hyatt, Scott K. Powers   +8 more
doaj   +2 more sources

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy. [PDF]

J Renin Angiotensin Aldosterone Syst, 2020
Introduction: The aims of this study were to assess the renal expression of angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor (AT2R), and MAS receptor in human type 2 diabetic nephropathy (DN). Materials and methods:
Ma YP, Yang Y, Jiang SM, Liu L, Zhang Z, Wang YN, Zou GM, Li WG.   +7 more
europepmc   +4 more sources

Unique mode of binding between angiotensin II type 1 receptor and its blockers

Clinical and Experimental Hypertension, 2019
BACKGROUND: We hypothesized that the 5-oxo-1,2,4-oxadiazole moiety of azilsartan (AZL), which represents a small difference in the molecular structures of AZL and candesartan (CAN) [angiotensin II type 1 receptor (AT1R) blockers], may be responsible for ...
Yoshino Matsuo, Yasunori Suematsu, Sayo Tomita, Kohei Tashiro, Takashi Kuwano, Ken Kitajima, Shin-ichiro Miura   +6 more
doaj   +3 more sources

Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. [PDF]

PLoS ONE, 2013
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are very similar, they are also slightly different. Although each ARB has been shown to exhibit a unique mode of binding to AT1 receptor, different positions ...
Shin-Ichiro Miura, Naoki Nakao, Hiroyuki Hanzawa, Yoshino Matsuo, Keijiro Saku, Sadashiva S Karnik   +5 more
doaj   +3 more sources

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. [PDF]

Korean J Intern Med, 2016
Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI).Between November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the ...
Lee JH, Bae MH, Yang DH, Park HS, Cho Y, Lee WK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Chae SC, Korea Acute Myocardial Infarction Registry Investigators.   +11 more
europepmc   +4 more sources

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19 [PDF]

Obesity, 2021
AbstractObjectiveSevere acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) uses the host’s angiotensin‐converting enzyme 2 (ACE2) as a cellular entry point. Therefore, modulating ACE2 might impact SARS‐CoV‐2 viral replication, shedding, and coronavirus disease 2019 (COVID‐19) severity.
Marlies de Ligt, Matthijs K. C. Hesselink, Johanna Jorgensen, Johan W. E. Jocken, Ellen E. Blaak, Gijs H. Goossens   +5 more
openaire   +3 more sources

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström   +3 more
doaj   +1 more source

Losartan improved hippocampal long‐term potentiation impairment induced by repeated LPS injection in rats

Physiological Reports, 2021
Cognitive impairment has been known as a common consequence of brain inflammation. Long‐term potentiation (LTP), the generally accepted cellular mechanism for memory formation in the mammalian brain, has been shown to be suppressed by inflammation ...
Mahmoud Hosseini, Hossein Salmani, Yousef Baghcheghi   +2 more
doaj   +1 more source

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19

Biomolecules, 2021
Angiotensin II (Ang II) may contain a charge relay system (CRS) involving Tyr/His/carboxylate, which creates a tyrosinate anion for receptor activation. Energy calculations were carried out to determine the preferred geometry for the CRS in the presence ...
Graham J. Moore, Jose M. Pires, Konstantinos Kelaidonis, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, John M. Matsoukas   +6 more
doaj   +1 more source